Glioblastoma is a rapidly growing type of brain tumor that falls under the category of gliomas, and it is recognized as one of the most aggressive and challenging cancers that medicine has encountered. For many years, the medical field has worked diligently to discover effective methods to combat this devastating illness. Although standard treatments like surgery, chemotherapy, and radiation can help to slow the progression of the disease, they seldom provide a lasting solution.
Recently, a novel approach utilizing CAR-T immunotherapy has yielded some truly remarkable outcomes. In a small clinical trial conducted in the US, patients suffering from recurrent glioblastoma experienced significant tumor shrinkage just days after starting treatment. While it is still in the early stages, this breakthrough has instilled a renewed sense of hope in both patients battling this type of cancer and the medical community, suggesting that this lethal disease may eventually be manageable.
Understanding glioblastoma
Glioblastoma, commonly referred to as glioblastoma multiforme or GBM, is the most aggressive and prevalent malignant brain tumor found in adults. It originates in the glial cells of the brain or spinal cord, which serve to support and protect our neurons. When these cells become cancerous, they begin to grow at an alarming rate and infiltrate the surrounding brain tissue.
Unlike most tumors that develop as organized masses, glioblastoma infiltrates surrounding areas, making it nearly impossible for surgeons to completely excise it during surgery. Even when surgeons think they have successfully removed the tumor, microscopic cells often remain, leading to a recurrence of the cancer.
Although glioblastoma can affect individuals of any age, it is most commonly found in older adults. The National Cancer Institute reports that some of the typical symptoms experienced by those with glioblastoma include persistent headaches, seizures, nausea, blurred vision, and difficulties with memory and speech. Since many of these symptoms overlap with various other neurological disorders, glioblastoma is often misdiagnosed in its later stages.
The scale of this disease is alarming. According to the charity Brain Tumour Research, approximately 3,200 individuals are diagnosed with glioblastoma each year in the UK alone.
Despite decades of research, the unfortunate truth is that the prognosis for glioblastoma patients remains bleak. The standard treatment regimen, known as the “triple threat,” which includes surgery followed by radiation and chemotherapy with drugs like temozolomide, can alleviate symptoms and slow progression, but rarely eliminates the disease entirely. For those diagnosed with this cancer, the average survival time post-diagnosis is typically around 15 months, highlighting the urgent need for researchers and medical professionals to explore new strategies for improved outcomes.
The difficulty of addressing solid tumors
One of the main challenges with glioblastoma lies in the very essence of solid tumors. Unlike blood cancers that circulate throughout the body, a tumor is fundamentally a mass of cells that creates its own internal environment.
Moreover, within a glioblastoma tumor, there can be various types of cancer cells, each with distinct genetic mutations. This phenomenon is known as tumor heterogeneity, and it poses a significant barrier to effectively treating glioblastoma. It complicates the process of eliminating all cancer cells simultaneously. Consequently, a treatment might seem effective initially, only for the cancer to return later as the resistant cells continue to proliferate.
Additionally, the brain itself presents its own protective mechanisms. While the blood-brain barrier is beneficial in shielding our brains from harmful substances, it also hinders medications from effectively reaching the tumor cells. These numerous challenges have compelled experts and researchers to seek innovative strategies for treating glioblastoma.
What is CAR-T therapy?
One of the most exciting advancements in cancer treatment recently is CAR-T therapy. CAR stands for Chimeric Antigen Receptor T cell therapy, which is essentially a type of personalized immunotherapy that harnesses the strength of our own immune system to combat and eliminate cancer cells within our bodies.
According to the American Cancer Society, the CAR-T therapy process starts with the collection of T cells from either the patient or a compatible donor. T cells are specialized immune cells that detect and fight against harmful invaders in our bodies. After collection, these T cells are sent to a laboratory where they are genetically modified to recognize specific proteins present on the surface of cancer cells. Once they have been re-engineered, the T cells are reintroduced into the body. Once in the bloodstream, these T cells focus on their target and destroy cancer cells.
To date, CAR-T therapy has demonstrated remarkable success in treating blood cancers like leukemia and lymphoma. There have been notable cases of patients with leukemia and lymphoma who had exhausted all other treatment options and then underwent CAR-T therapy, resulting in long-term remission.
Nevertheless, challenges remain in applying this therapy to treat solid tumors, such as glioblastoma.
A novel strategy for CAR-T therapy
Researchers from the Mass General Cancer Center, which is part of the Mass General Brigham healthcare system in Boston, have shared encouraging findings regarding a new CAR-T therapy aimed specifically at glioblastoma.
This information was released in March 2024 and has been featured in The New England Journal of Medicine, recognized as one of the leading medical journals globally.
As stated by Mass General Brigham, this research explored a new method that combines CAR-T cells with unique antibodies known as T-cell-engaging antibody molecules (TEAMs).
This innovative combination is designed to overcome one of the major challenges in glioblastoma treatment, which is the tumor’s genetic diversity. Rather than focusing on a single cancer marker, the therapy is crafted to target various types of tumor cells simultaneously.
Dr. Bryan Choi, a neurosurgeon and associate director of the Center for Brain Tumor Immunology and Immunotherapy at Mass General Cancer Center, highlighted the significance of this therapy.
“The CAR-T platform has transformed our approach to cancer treatment, but solid tumors like glioblastoma have posed significant challenges because not all cancer cells are identical, and there is variability among the cells within the tumor,” Choi remarked.
Additionally, Dr. Choi noted that by merging two therapeutic approaches, researchers can now address glioblastoma in a more comprehensive and potentially more effective manner.
The initial clinical trial included three patients who experienced recurring glioblastoma after standard treatments, which encompassed surgery, radiation, and chemotherapy.
Each patient received a single infusion of the modified CAR-T cells, and the outcomes were remarkable.
According to a study published in The New England Journal of Medicine, one patient saw an 18.5 percent reduction in their tumor just two days after starting the treatment. By day 69, imaging scans revealed that the tumor had decreased by 60.7 percent, and this positive response lasted for over six months.
Another patient also experienced a rapid regression of their tumor.
The most remarkable case involved a 57-year-old woman, who, as reported by Mass General Brigham, exhibited nearly complete regression of her tumor just five days after receiving a single infusion of this therapy, as evidenced by her MRI scan.
Given that this disease is notoriously difficult to treat, such results are quite uncommon.
Safety and Side Effects
While the results were promising, it is important to mention that there were some temporary side effects associated with the treatment.
The researchers noted that nearly all patients experienced fever and temporary neurological symptoms, including confusion or changes in mental status, shortly after the infusion. These side effects are typical of CAR-T therapy, as the immune system is significantly stimulated to combat cancer cells.
Patients were carefully observed during their hospital stay prior to being discharged.
Progress has been made, but a cure is still out of reach.
The outcomes observed in the three patients whose tumors have decreased in size are being called extraordinary; however, researchers emphasize that this does not yet qualify as a cure for glioblastoma.
Eventually, the tumors in all three patients began to grow again, and scientists believe this is likely due to the insufficient number of T cells present in their bodies.
Mass General Brigham reports that researchers are actively seeking ways to enhance the longevity of the treatment for glioblastoma patients, which may involve repeated CAR-T infusions or combining the therapy with chemotherapy to boost the immune response.
Dr. Elizabeth Gerstner, a neuro-oncologist at Massachusetts General Hospital and co-author of the study, underscores the necessity for continued research despite the advancements highlighted by the recent findings.
“We report a dramatic and rapid response in these three patients,” Gerstner stated. “Our work so far indicates that we are making progress, but there is still more to accomplish.”
Currently, CAR-T therapy stands as one of the most personalized methods for cancer treatment.
By utilizing the immune cells from the body, researchers can develop treatments customized to meet the unique requirements of each cancer patient.
Future studies may confirm these initial findings, and CAR-T therapy could open up new treatment possibilities not only for glioblastoma but for various other cancer types as well.
As Dr. Marcela Maus, director of the Cellular Immunotherapy Program at Mass General Cancer Center, noted in the Mass General Brigham report, the ultimate objective remains ambitious.
“We haven’t cured patients yet, but that is our audacious goal.”
*Medical disclaimer: The content of this article is meant solely for general informational purposes. It should not be interpreted as medical advice. The treatment mentioned is currently being studied in clinical trials, and additional research is required before it can be widely accessible. Always seek the guidance of a healthcare professional concerning medical issues or treatment alternatives.
